American Heart Journal
Volume 156, Issue 2, Supplement , Pages 1S-2S , August 2008

Platelet inhibitor therapy: Current perspectives and emerging novel agents: Introduction

  • Dominick J. Angiolillo, MD, PhD, FACC, FESC

      Affiliations

    • Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL
    • Corresponding Author InformationReprint requests: Dominick J. Angiolillo, MD, PhD, FACC, FESC, Division of Cardiology, University of Florida-Shands Jacksonville, 655 West 8th St, Jacksonville, FL 32209.
    • ,
  • Eric R. Bates, MD, FACC

      Affiliations

    • Division of Cardiology, University of Michigan, Ann Arbor, MI

References 

  1. Yusuf S, Zhao F, Mehta SR, et al. for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  2. Mehta SR, Yusuf S, Peters RJ, et al. for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533
  3. Steinhubl SR, Berger PB, Mann JT, et al. for the CREDO Investigators. Clopidogrel for the Reduction of Events During Observation Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO). JAMA. 2002;288:2411–2420
  4. Sabatine MS, Cannon CP, Gibson CM, et al. for the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. CLARITY-TIMI 28 Investigators. N Engl J Med. 2005;352:1179–1189
  5. Sabatine MS, Cannon CP, Gibson CM, et al. for the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294:1224–1232
  6. Chen ZM, Jiang LX, Chen YP, et al. for the COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–1621
  7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness of clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol. 2007;49:1505–1516

 Conflicts of Interest: Dominick J. Angiolillo, MD, PhD, FACC, FESC has declared the following conflicts of interest: Honoraria/Lectures: Bristol Myers Squibb (New York, NY); Sanofi-Aventis (Bridgewater, J); Eli Lilly and Company (Indianapolis, IN); Daiichi Sankyo, Inc (Parsippany, NJ). Honoraria/Advisory board: Bristol Myers Squibb; Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc.; The Medicines Company (Parsippany, NJ); Portola (San Francisco, CA); Novartis (East Hanover, NJ). Research Grants: GlaxoSmithKline (Brentford, London, United Kingdom); Otsuka (Tokyo, Japan). Eric R. Bates, MD, FACC has declared the following conflicts of interest: Honoraria/Lectures: Sanofi-Aventis; Hoffmann-La Roche (Nutley, NJ). Honoraria/Advisory board: Eli Lilly Co; The Medicines Company; Daiichi Sankyo, Inc.; Medicure Pharma (Winnipeg, Manitoba, Canada). Research Grants: Eli Lilly and Company.

PII: S0002-8703(08)00469-9

doi: 10.1016/j.ahj.2008.06.002

American Heart Journal
Volume 156, Issue 2, Supplement , Pages 1S-2S , August 2008

Article Tools